Simulations Plus (NASDAQ:SLP) specializes in creating simulation and modeling software for pharmaceutical research and development. With a focus on advancing drug discovery and development, the company offers a suite of software products designed to predict properties of molecules with high accuracy. These solutions enable researchers and biotech companies to make more informed decisions earlier in the drug development process, reducing time and costs associated with bringing new therapies to market. Simulations Plus also provides consulting services, leveraging its software capabilities to offer customized solutions that meet the specific needs of its clients. The company's objective is to remain at the forefront of technological innovation, continuously improving its offerings to support the evolving needs of the global pharmaceutical industry.